On Air Now

Current Show

Health Talk   9:00 PM - 10:00 PM

Call in to “Health Talk” with Dr. Ronald Hoffman at 800-544-7070.

Show Info »

Upcoming Shows

Program Schedule »

Tune in to Listen

650 AM Hibbing, Minnesota

Weather

Current Conditions(Hibbing,MN 55746)

More Weather »
56° Feels Like: 56°
Wind: S 5 mph Past 24 hrs - Precip: 0.17”
Current Radar for Zip

Tonight

Isolated Thunderstorms 51°

Tomorrow

PM Thunderstorms 77°

Thurs Night

Scattered Thunderstorms 60°

Alerts

  • 0 Severe Weather Alerts
  • 0 Cancellations

AstraZeneca to co-promote J&J prostate cancer drug in Japan

LONDON (Reuters) - AstraZeneca has signed a deal to co-promote Johnson & Johnson's novel prostate cancer medicine in Japan, giving the British company a new drug revenue stream and bolstering its Japanese presence.

Financial terms of the agreement, announced by AstraZeneca on Friday, were not disclosed.

The drug, abiraterone, was submitted for regulatory approval in Japan in July 2013. It is already on the market in the United States and Europe, where it is sold under the brand name Zytiga.

"This deal is a strong strategic fit for AstraZeneca, reinforcing both our focus on oncology as a core therapy area and Japan as one of our key growth drivers," said Marc Dunoyer, executive vice president for global products and portfolio strategy at AstraZeneca.

(Reporting by Ben Hirschler; Editing by David Holmes)

Comments